Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

114 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Identification of leptomeningeal disease in aggressive B-cell non-Hodgkin's lymphoma: improved sensitivity of flow cytometry.
Quijano S, López A, Manuel Sancho J, Panizo C, Debén G, Castilla C, Antonio García-Vela J, Salar A, Alonso-Vence N, González-Barca E, Peñalver FJ, Plaza-Villa J, Morado M, García-Marco J, Arias J, Briones J, Ferrer S, Capote J, Nicolás C, Orfao A; Spanish Group for the Study of CNS Disease in NHL. Quijano S, et al. J Clin Oncol. 2009 Mar 20;27(9):1462-9. doi: 10.1200/JCO.2008.17.7089. Epub 2009 Feb 17. J Clin Oncol. 2009. PMID: 19224854
Rituximab, fludarabine, cyclophosphamide, and mitoxantrone: a new, highly active chemoimmunotherapy regimen for chronic lymphocytic leukemia.
Bosch F, Abrisqueta P, Villamor N, Terol MJ, González-Barca E, Ferra C, González Diaz M, Abella E, Delgado J, Carbonell F, García Marco JA, Escoda L, Ferrer S, Monzó E, González Y, Estany C, Jarque I, Salamero O, Muntañola A, Montserrat E. Bosch F, et al. J Clin Oncol. 2009 Sep 20;27(27):4578-84. doi: 10.1200/JCO.2009.22.0442. Epub 2009 Aug 24. J Clin Oncol. 2009. PMID: 19704063 Clinical Trial.
Autologous stem cell transplantation after conditioning with yttrium-90 ibritumomab tiuxetan BEAM in refractory non-Hodgkin diffuse large B-cell lymphoma: results of a prospective, multicenter, phase II clinical trial.
Briones J, Novelli S, García-Marco JA, Tomás JF, Bernal T, Grande C, Canales MA, Torres A, Moraleda JM, Panizo C, Jarque I, Palmero F, Hernández M, González-Barca E, López D, Caballero D; Grupo Español de Linfomas y Trasplante Autologo de Médula Ósea (GELTAMO). Briones J, et al. Haematologica. 2014 Jul;99(7):e126. doi: 10.3324/haematol.2014.108308. Haematologica. 2014. PMID: 24986878 Free PMC article. No abstract available.
High prognostic value of measurable residual disease detection by flow cytometry in chronic lymphocytic leukemia patients treated with front-line fludarabine, cyclophosphamide, and rituximab, followed by three years of rituximab maintenance.
García-Marco JA, Jiménez JL, Recasens V, Zarzoso MF, González-Barca E, De Marcos NS, Ramírez MJ, Parraga FJP, Yañez L, De La Serna Torroba J, Malo MDG, Ariznavarreta GD, Persona EP, Guinaldo MAR, De Paz Arias R, Llanos EB, Jarque I, Valle MDCF, Tatay AC, De Oteyza JP, Martin EMD, Fernández IP, Martinez RM, Costa MAA, Champ D, Suarez JG, Díaz MG, Ferrer S, Carbonell F, García-Vela JA; GELLC Study Group. García-Marco JA, et al. Haematologica. 2019 Nov;104(11):2249-2257. doi: 10.3324/haematol.2018.204891. Epub 2019 Mar 19. Haematologica. 2019. PMID: 30890600 Free PMC article.
Autologous stem cell transplantation after conditioning with yttrium-90 ibritumomab tiuxetan plus BEAM in refractory non-Hodgkin diffuse large B-cell lymphoma: results of a prospective, multicenter, phase II clinical trial.
Briones J, Novelli S, García-Marco JA, Tomás JF, Bernal T, Grande C, Canales MA, Torres A, Moraleda JM, Panizo C, Jarque I, Palmero F, Hernández M, González-Barca E, López D, Caballero D; GELTAMO. Briones J, et al. Haematologica. 2014 Mar;99(3):505-10. doi: 10.3324/haematol.2013.093450. Epub 2013 Oct 25. Haematologica. 2014. PMID: 24162789 Free PMC article. Clinical Trial.
Central nervous system prophylaxis with intrathecal liposomal cytarabine in a subset of high-risk patients with diffuse large B-cell lymphoma receiving first line systemic therapy in a prospective trial.
González-Barca E, Canales M, Salar A, Ferreiro-Martínez JJ, Ferrer-Bordes S, García-Marco JA, Sánchez-Blanco JJ, García-Frade J, Peñalver J, Bello-López JL, Sancho JM, Caballero D; GELTAMO group. González-Barca E, et al. Ann Hematol. 2016 May;95(6):893-9. doi: 10.1007/s00277-016-2648-4. Epub 2016 Mar 30. Ann Hematol. 2016. PMID: 27025508 Free PMC article.
A randomized phase II study comparing consolidation with a single dose of 90Y ibritumomab tiuxetan vs. maintenance with rituximab for two years in patients with newly diagnosed follicular lymphoma responding to R-CHOP. Long-term follow-up results.
López-Guillermo A, Canales MÁ, Dlouhy I, Mercadal S, Briones J, Martín García-Sancho A, Sancho JM, Moraleda JM, Terol MJ, Salar A, Palomera L, Gardella S, Jarque I, Ferrer S, Bargay J, López A, Panizo C, Muntañola A, Montalbán C, Conde E, Hernández MT, Soler A, García Marco JA, Deben G, Marín J, Tomás JF; PETHEMA/GELTAMO/GELCAB Spanish Intergroup. López-Guillermo A, et al. Among authors: garcia marco ja. Leuk Lymphoma. 2022 Jan;63(1):93-100. doi: 10.1080/10428194.2021.1971216. Epub 2021 Aug 30. Leuk Lymphoma. 2022. PMID: 34459702 Clinical Trial.
Genomic mutation profile in progressive chronic lymphocytic leukemia patients prior to first-line chemoimmunotherapy with FCR and rituximab maintenance (REM).
González-Rincón J, Garcia-Vela JA, Gómez S, Fernández-Cuevas B, Nova-Gurumeta S, Pérez-Sanz N, Alcoceba M, González M, Anguita E, López-Jiménez J, González-Barca E, Yáñez L, Pérez-Persona E, de la Serna J, Fernández-Zarzoso M, Deben G, Peñalver FJ, Fernández MC, de Oteyza JP, Andreu MÁ, Ruíz-Guinaldo MÁ, Paz-Arias R, García-Malo MD, Recasens V, Collado R, Córdoba R, Navarro-Matilla B, Sánchez-Beato M, García-Marco JA. González-Rincón J, et al. Among authors: garcia marco ja. PLoS One. 2021 Sep 10;16(9):e0257353. doi: 10.1371/journal.pone.0257353. eCollection 2021. PLoS One. 2021. PMID: 34506616 Free PMC article.
Incidence and prognostic impact of secondary cytogenetic aberrations in a series of 145 patients with mantle cell lymphoma.
Espinet B, Salaverria I, Beà S, Ruiz-Xivillé N, Balagué O, Salido M, Costa D, Carreras J, Rodríguez-Vicente AE, Luís García J, Hernández-Rivas JM, Calasanz MJ, Siebert R, Ferrer A, Salar A, Carrió A, Polo N, García-Marco JA, Domingo A, González-Barca E, Romagosa V, Marugán I, López-Guillermo A, Millá F, Luís Mate J, Luño E, Sanzo C, Collado R, Oliver I, Monzó S, Palacín A, González T, Sant F, Salinas R, Ardanaz MT, Font L, Escoda L, Florensa L, Serrano S, Campo E, Solé F. Espinet B, et al. Genes Chromosomes Cancer. 2010 May;49(5):439-51. doi: 10.1002/gcc.20754. Genes Chromosomes Cancer. 2010. PMID: 20143418
114 results